Jump to content
  • Sign Up
  • Join Our Community!

    Get help in our celiac / gluten-free forum.

  • Scott Adams
    Scott Adams

    Numerate Awarded Phase 1 NIH Grant to Support Design of New Therapies for Celiac Disease

    Reviewed and edited by a celiac disease expert.

    Celiac.com 03/19/2009 - Numerate Inc., a biotechnology company leveraging a novel drug engineering process to design lead-stage drug compounds, announced today it has received a Phase 1 grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH). The Small Business Technology Transfer (STTR) award, entitled “Drug Engineering of Transglutaminase 2 Inhibitors,” will be used to support a research collaboration between Numerate and the laboratory of Chaitan Khosla, Ph.D., the Wells H. Rauser and Harold M. Petiprin Professor of Chemical Engineering and Chemistry at Stanford University.

    “This NIH Phase 1 STTR award validates the attractiveness of Numerate’s drug engineering process for the design of new small molecule drugs,” stated John Griffin, Ph.D., Numerate’s chief scientific officer and principal investigator of the project. “In addition, it recognizes the potential of transglutaminase 2 inhibitors for the treatment of Celiac Sprue. Professor Khosla is a leader in Celiac disease research, and we are pleased to have the support of the NIH in our collaboration with him and his laboratory.”

    Professor Khosla, who will serve as co-investigator for the STTR research project, added, “Transglutaminase 2 is central to the pathophysiology of Celiac Sprue, and offers a compelling target for a disease for which no pharmacotherapy currently exists. I look forward to having Numerate apply its breakthrough technology to this important problem.”

    Celiac Sprue, also known as celiac disease, is an autoimmune disorder of the small intestine involving intolerance to gluten proteins found in wheat and other grains.

    About Numerate

    Numerate is a privately held biotechnology company that has developed and extensively validated a drug engineering process that rapidly and cost-effectively delivers small molecule drug candidates optimized for efficacy, safety, and patentability. Numerate’s drug engineering process combines advances in computer science, statistics, and molecular modeling to address, in parallel, the factors that determine the success and failure of a drug. Numerate applies this proprietary process to design and develop small molecule therapeutics in collaboration with a variety of partners in the pharmaceutical and biotechnology fields. For more information, please visit www.numerate.com.


    User Feedback

    Recommended Comments

    There are no comments to display.



    Join the conversation

    You are posting as a guest. If you have an account, sign in now to post with your account.
    Note: Your post will require moderator approval before it will be visible.

    Guest
    Add a comment...

    ×   Pasted as rich text.   Paste as plain text instead

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.


  • About Me

    Celiac.com's Founder and CEO, Scott was diagnosed with celiac disease  in 1994, and, due to the nearly total lack of information available at that time, was forced to become an expert on the disease in order to recover. Scott launched the site that later became Celiac.com in 1995 "To help as many people as possible with celiac disease get diagnosed so they can begin to live happy, healthy gluten-free lives."  In 1998 he founded The Gluten-Free Mall which he sold in 2014. He is co-author of the book Cereal Killers, and founder and publisher of Journal of Gluten Sensitivity.

  • Related Articles

    Jefferson Adams
    Celiac.com 09/28/2012 - Two researchers recently set out to study gluten sensitivity in people without celiac disease. The study was conducted by A. Di Sabatino A, and G.R. Corazza of the Centro per lo Studio e la Curia della Mallatia Celiaca at the Fondazione IRCCS Policlinico San Matteo at the University of Pavia in Italy.
    A number of studies support the existence non-celiac ...

    Jefferson Adams
    Celiac.com 11/22/2013 - Timing of gluten introduction has been associated with the risk of celiac disease in children, but the best time window for gluten introduction had remained unknown.
    In order to determine the optimal time window for gluten introduction in children, a team of researchers recently set out to assess the effect of age at first gluten consumption on the risk...

    Jefferson Adams
    Celiac.com 07/02/2014 - Each year, non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, acetaminophen, and aspirin, send more than 100,000 people to the hospital, and cause over 16,000 deaths. These drugs are marketed under brand names such as Advil and aspirin, among others.
    In some ways, these findings are unsurprising. Studies from as far back as the 1980s have...

  • Forum Discussions

    Thank you knitty kitty and posterboy. I do take my multi that has it in it. I may have to look for a liquid form. thank you for reaching out I very much want to find some stability as I am working now and need to be a good wife, mom,...
    Awol, I saw this earlier...but got busy with life...Knitty Kitty's response triggered my memory...POTS has been associated with low Thiamine Levels...they say as many as 1/4 of those with POTS might improve after taking thiamine supplementation...
    You can try the AIP diet. It is very effective for treating IBS. Migraines are often linked to IBS. https://autoimmunewellness.com/aip-medical-study-results/ Also NAC an antioxidant that can cross the blood brain barrier. http...
×
×
  • Create New...